{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:43:13Z","timestamp":1761673393584,"version":"build-2065373602"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"DOI":"10.7759\/cureus.95602","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:25:46Z","timestamp":1761672346000},"source":"Crossref","is-referenced-by-count":0,"title":["Recent Trends in the Pharmacological Treatment of Chronic Migraine: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Jitender","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00452-3","article-title":"Effectiveness and safety of chronic migraine preventive treatments: a systematic literature review","volume":"12","author":"Blumenfeld AM","year":"2023","unstructured":"Blumenfeld AM, Kaur G, Mahajan A, Shukla H, Sommer K, Tung A, Knievel KL. Effectiveness and safety of chronic migraine preventive treatments: a systematic literature review. Pain Ther. 2023, 12:251-74. 10.1007\/s40122-022-00452-3","journal-title":"Pain Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0621-8","article-title":"Current prophylactic medications for migraine and their potential mechanisms of action","volume":"15","author":"Sprenger T","year":"2018","unstructured":"Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018, 15:313-23. 10.1007\/s13311-018-0621-8","journal-title":"Neurotherapeutics"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221607","article-title":"Pharmacologic prevention of migraine","volume":"195","author":"Tzankova V","year":"2023","unstructured":"Tzankova V, Becker WJ, Chan TL. Pharmacologic prevention of migraine. CMAJ. 2023, 195:E187-92. 10.1503\/cmaj.221607","journal-title":"CMAJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01696-w","article-title":"Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis","volume":"24","author":"Naghdi S","year":"2023","unstructured":"Naghdi S, Underwood M, Madan J, et al.. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. J Headache Pain. 2023, 24:164. 10.1186\/s10194-023-01696-w","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2022.873179","article-title":"New approaches to shifting the migraine treatment paradigm","volume":"3","author":"Johnson B","year":"2022","unstructured":"Johnson B, Freitag FG. New approaches to shifting the migraine treatment paradigm. Front Pain Res (Lausanne). 2022, 3:873179. 10.3389\/fpain.2022.873179","journal-title":"Front Pain Res (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst F","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021, 22:128. 10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989601","article-title":"Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis","volume":"41","author":"Drellia K","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia. 2021, 41:851-64. 10.1177\/0333102421989601","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.345","article-title":"Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date","volume":"6","author":"Pellesi L","year":"2017","unstructured":"Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017, 6:534-47. 10.1002\/cpdd.345","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070700","article-title":"Monoclonal antibodies targeting CGRP: from clinical studies to real-world evidence-what do we know so far?","volume":"14","author":"Mavridis T","year":"2021","unstructured":"Mavridis T, Deligianni CI, Karagiorgis G, Daponte A, Breza M, Mitsikostas DD. Monoclonal antibodies targeting CGRP: from clinical studies to real-world evidence-what do we know so far?. Pharmaceuticals (Basel). 2021, 14:700. 10.3390\/ph14070700","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231177636","article-title":"Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: a real-world evidence study","volume":"43","author":"Alpuente A","year":"2023","unstructured":"Alpuente A, Torre-Sune A, Caronna E, Gine-Cipres E, Torres-Ferr\u00fas M, Pozo-Rosich P. Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: a real-world evidence study. Cephalalgia. 2023, 43:3331024231177636. 10.1177\/03331024231177636","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06199-1","article-title":"The ultimate guide to the anti-CGRP monoclonal antibodies galaxy","volume":"43","author":"Mascarella D","year":"2022","unstructured":"Mascarella D, Matteo E, Favoni V, Cevoli S. The ultimate guide to the anti-CGRP monoclonal antibodies galaxy. Neurol Sci. 2022, 43:5673-85. 10.1007\/s10072-022-06199-1","journal-title":"Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/head.13956","article-title":"Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study","volume":"60","author":"Alex A","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache. 2020, 60:2454-62. 10.1111\/head.13956","journal-title":"Headache"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12393","article-title":"Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine","volume":"21","author":"Diener HC","year":"2014","unstructured":"Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014, 21:851-9. 10.1111\/ene.12393","journal-title":"Eur J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora SK","year":"2014","unstructured":"Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014, 129:61-70. 10.1111\/ane.12171","journal-title":"Acta Neurol Scand"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein SD","year":"2015","unstructured":"Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015, 86:996-1001. 10.1136\/jnnp-2013-307149","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416652092","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program","volume":"36","author":"Lipton RB","year":"2016","unstructured":"Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia. 2016, 36:899-908. 10.1177\/0333102416652092","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0784-4","article-title":"The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis","volume":"18","author":"Matharu M","year":"2017","unstructured":"Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain. 2017, 18:78. 10.1186\/s10194-017-0784-4","journal-title":"J Headache Pain"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke HC","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018, 91:e2211-21. 10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3","article-title":"Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24\u2009weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study","volume":"21","author":"Silberstein S","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, et al.. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24\u2009weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020, 21:120. 10.1186\/s10194-020-01186-3","journal-title":"J Headache Pain"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207168","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"101","year":"2023","unstructured":"Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2023, 101:283. 10.1212\/WNL.0000000000207168","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study","volume":"61","author":"Lipton RB","year":"2021","unstructured":"Lipton RB, Cohen JM, Galic M, et al.. Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache. 2021, 61:662-72. 10.1111\/head.14097","journal-title":"Headache"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02623-1","article-title":"Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)","volume":"30","author":"Ford J","year":"2021","unstructured":"Ford J, Tassorelli C, Leroux E, Wang S, Ayer D, Nichols R, Detke H. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Qual Life Res. 2021, 30:105-15. 10.1007\/s11136-020-02623-1","journal-title":"Qual Life Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01482-0","article-title":"Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study","volume":"23","author":"Cowan RP","year":"2022","unstructured":"Cowan RP, Marmura MJ, Diener HC, et al.. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. J Headache Pain. 2022, 23:115. 10.1186\/s10194-022-01482-0","journal-title":"J Headache Pain"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2109335","article-title":"Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)","volume":"25","author":"Tobin JA","year":"2022","unstructured":"Tobin JA, Joshi S, Ford JH, et al.. Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN). J Med Econ. 2022, 25:1030-8. 10.1080\/13696998.2022.2109335","journal-title":"J Med Econ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221089567","article-title":"Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine","volume":"42","author":"McAllister P","year":"2022","unstructured":"McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A. Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia. 2022, 42:1005-12. 10.1177\/03331024221089567","journal-title":"Cephalalgia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12809-z","article-title":"Eptinezumab treatment was associated with longer interictal headache\/migraine periods which corresponded to greater improvements in patient-reported quality of life measures","volume":"272","author":"Tepper SJ","year":"2024","unstructured":"Tepper SJ, Diamond ML, Hirman J, Asher D, Fiore D, Cady R. Eptinezumab treatment was associated with longer interictal headache\/migraine periods which corresponded to greater improvements in patient-reported quality of life measures. J Neurol. 2024, 272:4. 10.1007\/s00415-024-12809-z","journal-title":"J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1355877","article-title":"Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review","volume":"15","author":"Irimia P","year":"2024","unstructured":"Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, L\u00e1inez JM. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol. 2024, 15:1355877. 10.3389\/fneur.2024.1355877","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"Ashina M","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al.. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022, 21:597-607. 10.1016\/S1474-4422(22)00185-5","journal-title":"Lancet Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/head.14767","article-title":"Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache","volume":"64","author":"Blumenfeld A","year":"2024","unstructured":"Blumenfeld A, Kudrow D, McAllister P, Boserup LP, Hirman J, Cady R. Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache. Headache. 2024, 64:738-49. 10.1111\/head.14767","journal-title":"Headache"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18032","article-title":"A review of eptinezumab use in migraine","volume":"13","author":"Datta A","year":"2021","unstructured":"Datta A, Maryala S, John R. A review of eptinezumab use in migraine. Cureus. 2021, 13:e18032. 10.7759\/cureus.18032","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener HC","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, et al.. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010, 30:804-14. 10.1177\/0333102410364677","journal-title":"Cephalalgia"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review","volume":"60","author":"Burstein R","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020, 60:1259-72. 10.1111\/head.13849","journal-title":"Headache"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.153","article-title":"OnabotulinumtoxinA improves quality of life in chronic migraine: the PREDICT study","volume":"49","author":"Boudreau G","year":"2022","unstructured":"Boudreau G, Finkelstein I, Graboski C, et al.. OnabotulinumtoxinA improves quality of life in chronic migraine: the PREDICT study. Can J Neurol Sci. 2022, 49:540-52. 10.1017\/cjn.2021.153","journal-title":"Can J Neurol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032600","article-title":"Treatment of chronic migraine with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Turkel CC","year":"2023","unstructured":"Turkel CC, Aurora S, Diener HC, Dodick DW, Lipton RB, Silberstein SD, Brin MF. Treatment of chronic migraine with Botox (onabotulinumtoxinA): development, insights, and impact. Medicine (Baltimore). 2023, 102:e32600. 10.1097\/MD.0000000000032600","journal-title":"Medicine (Baltimore)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: a review in the prevention of chronic migraine","volume":"78","author":"Frampton JE","year":"2018","unstructured":"Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018, 78:589-600. 10.1007\/s40265-018-0894-6","journal-title":"Drugs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora SK","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC, et al.. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011, 51:1358-73. 10.1111\/j.1526-4610.2011.01990.x","journal-title":"Headache"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02022.x","article-title":"Insights into the mechanism of onabotulinumtoxinA in chronic migraine","volume":"51","author":"Durham PL","year":"2011","unstructured":"Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011, 51:1573-7. 10.1111\/j.1526-4610.2011.02022.x","journal-title":"Headache"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01319-9","article-title":"Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review","volume":"37","author":"Martin V","year":"2020","unstructured":"Martin V, Samaan KH, Aurora S, Pearlman EM, Zhou C, Li X, Pallay R. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020, 37:2034-49. 10.1007\/s12325-020-01319-9","journal-title":"Adv Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419847957","article-title":"Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure","volume":"39","author":"Ruff DD","year":"2019","unstructured":"Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al.. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia. 2019, 39:931-44. 10.1177\/0333102419847957","journal-title":"Cephalalgia"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2799","article-title":"Galcanezumab for the treatment of chronic migraine and medication overuse headache: real-world clinical evidence in a severely impaired patient population","volume":"13","author":"Guerzoni S","year":"2023","unstructured":"Guerzoni S, Baraldi C, Castro FL, Cainazzo MM, Pani L. Galcanezumab for the treatment of chronic migraine and medication overuse headache: real-world clinical evidence in a severely impaired patient population. Brain Behav. 2023, 13:e2799. 10.1002\/brb3.2799","journal-title":"Brain Behav"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2059975","article-title":"Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study","volume":"38","author":"Pozo-Rosich P","year":"2022","unstructured":"Pozo-Rosich P, Detke HC, Wang S, Dole\u017eil D, Li LQ, Aurora SK, Reuter U. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022, 38:731-42. 10.1080\/03007995.2022.2059975","journal-title":"Curr Med Res Opin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394104-recent-trends-in-the-pharmacological-treatment-of-chronic-migraine-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:25:47Z","timestamp":1761672347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394104-recent-trends-in-the-pharmacological-treatment-of-chronic-migraine-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.95602","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}